Prognostic significance of vascular endothelial growth factor expression in clear cell renal cell carcinoma

被引:57
作者
Djordjevic, Gordana
Mozetic, Vladimir
Mozetic, Danijela Vrdoljak
Licul, Vanja
Ilijas, Koviljka Matusan
Mustac, Elvira
Oguic, Romano
Fuckar, Zeljko
Jonjic, Nives
机构
[1] Rijeka Univ, Sch Med, Dept Pathol, HR-51000 Rijeka, Croatia
[2] Rijeka Univ, Ctr Hosp, Dept Urol, HR-51000 Rijeka, Croatia
[3] Rijeka Univ, Ctr Hosp, Dept Gynecol Cytol, Dept Gynecol & Obstet, HR-51000 Rijeka, Croatia
关键词
carcinoma; renal cell; CD31; VEGF; survival rate;
D O I
10.1016/j.prp.2006.12.002
中图分类号
R36 [病理学];
学科分类号
100104 [病理学与病理生理学];
摘要
The purpose of this investigation was to analyze and correlate the immunohistochemical pattern of vascular endothelial growth factor (VEGF) expression with the average of microvessel density (MVD) and other clinicopathologic parameters in clear cell renal cell carcinoma (CCRCC) in order to determine its prognostic significance. Surgical specimens of 93 CCRCC were immunohistochemically analyzed for VEGF expression, MVD with anti-CD31, and Ki 67 proliferative index. VEGF expression was recorded as the percentage of positive tumor cells (< 75% and > 75%) and as diffuse or perimembranous VEGF expression according to cytoplasmic distribution. Sixty-three (68%) RCC had < 75% and 30 had (32%) > 75% of VEGF expression. A diffuse cytoplasmic pattern of VEGF expression was found in 61(66%) RCC and a perimembranous one in 32 (34%) RCC. Statistical analysis showed that tumors with > 75% of VEGF expression were characterized by lower MVD value (p = 0.034), higher nuclear grade (p = 0.018), and higher Ki 67 proliferation index (p = 0.023). Moreover, a higher nuclear grade of tumor cells was characterized by diffuse cytoplasmic VEGF distribution (p = 0.005). This tumor model did not confirm the postulated simple relationship between VEGF overexpression and angiogenesis through high microvessel count. However, the study results indicated that overexpression of VEGF was a worse histologic prognostic parameter in CCRCC. (c) 2007 Elsevier GmbH. All rights reserved.
引用
收藏
页码:99 / 106
页数:8
相关论文
共 40 条
[1]
[Anonymous], [No title captured]
[2]
[Anonymous], EAU UPDAT SER
[3]
EXPRESSION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) AND ITS RECEPTORS IN BREAST-CANCER [J].
BROWN, LF ;
BERSE, B ;
JACKMAN, RW ;
TOGNAZZI, K ;
GUIDI, AJ ;
DVORAK, HF ;
SENGER, DR ;
CONNOLLY, JL ;
SCHNITT, SJ .
HUMAN PATHOLOGY, 1995, 26 (01) :86-91
[4]
BROWN LF, 1993, CANCER RES, V53, P4727
[5]
Cornali E, 1996, AM J PATHOL, V149, P1851
[6]
Dosquet C, 1997, CLIN CANCER RES, V3, P2451
[7]
DISTRIBUTION OF VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) IN TUMORS - CONCENTRATION IN TUMOR BLOOD-VESSELS [J].
DVORAK, HF ;
SIOUSSAT, TM ;
BROWN, LF ;
BERSE, B ;
NAGY, JA ;
SOTREL, A ;
MANSEAU, EJ ;
VANDEWATER, L ;
SENGER, DR .
JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 174 (05) :1275-1278
[8]
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [J].
Eisen, T ;
Boshoff, C ;
Mak, I ;
Sapunar, F ;
Vaughan, MM ;
Pyle, L ;
Johnston, SRD ;
Ahern, R ;
Smith, IE ;
Gore, ME .
BRITISH JOURNAL OF CANCER, 2000, 82 (04) :812-817
[9]
PITUITARY FOLLICULAR CELLS SECRETE A NOVEL HEPARIN-BINDING GROWTH-FACTOR SPECIFIC FOR VASCULAR ENDOTHELIAL-CELLS [J].
FERRARA, N ;
HENZEL, WJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 161 (02) :851-858
[10]
PROGNOSTIC-SIGNIFICANCE OF MORPHOLOGIC PARAMETERS IN RENAL-CELL CARCINOMA [J].
FUHRMAN, SA ;
LASKY, LC ;
LIMAS, C .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1982, 6 (07) :655-663